Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
9.06
-0.01 (-0.11%)
Oct 10, 2025, 1:24 PM EDT - Market open
Mersana Therapeutics Revenue
Mersana Therapeutics had revenue of $3.06M in the quarter ending June 30, 2025, with 33.28% growth. This brings the company's revenue in the last twelve months to $34.77M, up 16.14% year-over-year. In the year 2024, Mersana Therapeutics had annual revenue of $40.50M with 9.88% growth.
Revenue (ttm)
$34.77M
Revenue Growth
+16.14%
P/S Ratio
1.29
Revenue / Employee
$340,873
Employees
102
Market Cap
45.22M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 40.50M | 3.64M | 9.88% |
Dec 31, 2023 | 36.86M | 10.27M | 38.65% |
Dec 31, 2022 | 26.58M | 26.54M | 61,716.28% |
Dec 31, 2021 | 43.00K | -785.00K | -94.81% |
Dec 31, 2020 | 828.00K | -41.30M | -98.03% |
Dec 31, 2019 | 42.12M | 31.53M | 297.61% |
Dec 31, 2018 | 10.59M | -6.95M | -39.62% |
Dec 31, 2017 | 17.55M | -7.63M | -30.30% |
Dec 31, 2016 | 25.17M | 14.81M | 142.99% |
Dec 31, 2015 | 10.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MRSN News
- 2 months ago - Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 - GlobeNewsWire
- 2 months ago - Mersana Therapeutics Announces 1-for-25 Reverse Stock Split - GlobeNewsWire
- 4 months ago - Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting - GlobeNewsWire
- 5 months ago - Mersana Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Mersana Therapeutics, Inc. (MRSN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 months ago - CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results - GlobeNewsWire